The global clinical trial supplies market was valued at USD 2.58 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 6.5% from 2024 to 2030. Several key factors contribute to this growth, including the globalization of clinical trials and the increasing number of biologic and biosimilar drugs under development. As biologics and biosimilars become a larger portion of clinical research, the complexity of managing clinical trial supplies also grows, driving the need for robust supply chain management systems. Efficient management of clinical trial supplies is critical, as they account for a significant portion of biopharmaceutical companies’ R&D expenses.

The adoption of advanced supply chain management systems helps companies reduce R&D costs and improve operational efficiency, both of which are essential in today’s competitive pharmaceutical landscape. Moreover, temperature-sensitive drugs and biologics which require specialized storage and transport are becoming more prevalent in clinical trials, further emphasizing the need for advanced supply management.

A large share of clinical trials is now being conducted in developing regions such as Asia Pacific, Latin America, Central & Eastern Europe, and the Middle East. This shift is primarily driven by the high costs and logistical challenges of conducting trials in developed economies, along with difficulties in patient recruitment. Developing regions offer lower operational costs and unique disease variations, making them attractive for testing drugs for rare diseases. In regions like Asia Pacific, governments actively support biomedical research by offering funding initiatives. For instance, China and Singapore allocate resources to boost clinical trial activities. Meanwhile, Latin America provides further advantages with fewer language barriers, enabling easier informed consent processes and faster recruitment of participants, thereby accelerating clinical trials.

Gather more insights about the market drivers, restrains and growth of the Clinical Trial Supplies Market

Product & Service Segmentation Insights:

Supply chain management dominated the market in 2023, accounting for the largest revenue share. This category includes the full range of processes necessary for ensuring the availability of clinical trial materials, from procurement and storage to distribution and logistics. Efficient supply chain management is essential for the smooth execution of clinical trials, as it ensures that drugs and other materials reach clinical sites on time.

While supply chain management plays a critical role in most regions globally, the U.S. market also sees substantial growth in manufacturing services, driven by efforts to become more self-reliant in pharmaceutical production. The COVID-19 pandemic exposed vulnerabilities in global supply chains, prompting the U.S. to focus more on domestic manufacturing to reduce dependence on foreign suppliers.

The clinical trial supplies industry is segmented into three major categories:

1. Manufacturing

2. Storage and distribution

3. Supply chain management

The manufacturing segment is expected to grow at a CAGR of over 6.6% during the forecast period. The increasing number of clinical trials worldwide has led to a surge in demand for drug materials and supplies, including biologics and complex molecules. Manufacturing quality drugs is becoming increasingly important to meet clinical trial requirements.

The growth in the manufacturing segment is largely driven by the outsourcing of material production. Outsourcing allows companies to take advantage of new technologies for manufacturing complex molecules and helps reduce costs by utilizing external expertise. This trend is especially relevant for biologics and biosimilars, as their development requires sophisticated manufacturing processes. With rising demand for cost-efficient production, companies are increasingly relying on contract manufacturing organizations (CMOs) to meet supply demands.

Outsourcing also aligns with the growing need for flexibility in drug development, enabling companies to scale production based on trial requirements. The involvement of external manufacturers ensures that biopharmaceutical companies can focus on R&D and clinical operations while minimizing operational overheads. This shift toward specialized manufacturing partnerships is expected to continue, as companies strive to enhance efficiency and cost-effectiveness in clinical trial supply management.

Order a free sample PDF of the Clinical Trial Supplies Market Intelligence Study, published by Grand View Research.